Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM

ASTEROID 1-Phase IIb-study results of vilaprisan in patients with symptomatic uterine fibroids

Bayer successfully closed syndication of USD 56.9 billion acquisition facilities

Bayer second in Good Company Ranking

Board of Management member Dr. Klusik: “Sustainability is a core element of our strategy”

Bayer receives green light for new five-year contraceptive in the EU

New low dose levonorgestrel-releasing intrauterine system will be named “Kyleena™” / Introduction in Europe is scheduled to start in January 2017

Bayer and DelSiTech Partner to Develop Innovative Drug Delivery Technology for Ophthalmology

Bayer comments on article in The British Medical Journal (BMJ) regarding Xarelto®

Bayer to Showcase Latest Oncology Research at ESMO 2016 Congress

Includes a late-breaking oral presentation of results from the Phase III RESORCE trial evaluating regorafenib in unresectable hepatocellular carcinoma (HCC) / Additional presentations include early pipeline data on Bayer’s investigational oral pan-fibroblast growth factor receptor (FGFR) inhibitor, and further data on radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC)